OncoMatch/Clinical Trials/NCT06912711
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Is NCT06912711 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Toripalimab and Nimotuzumab for nasopharyngeal carcinoma.
Treatment: Toripalimab · Nimotuzumab — Investigators target recurrent nasopharyngeal carcinoma that can be resected surgically: rT1, rT2 (tumor confined to the surface of the parapharyngeal space, greater than 0.5cm from the internal carotid artery), rT3 (confined to the floor of the sphenoid sinus, greater than 0.5cm from the internal carotid artery/cavernous sinus) (AJCC 8th stage), A single-arm, phase II clinical trial was designed to investigate the efficacy and safety of triplizumab combined with nituzumab in induction and adjuvant treatment of operable local recurrent nasopharyngeal carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT1, RT2, RT3
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radiation therapy
Patients with recurrence time more than 6 months from the end of radiotherapy
Cannot have received: systemic or local glucocorticoid therapy
Received systemic or local glucocorticoid therapy within 4 weeks before enrollment
Cannot have received: other drug clinical trials
Patients who have participated in other drug clinical trials within 3 months before treatment
Lab requirements
Blood counts
Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L
Kidney function
serum creatinine <1.5×ULN
Liver function
ALT and AST < 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN
Cardiac function
no serious dysfunction of heart
no serious dysfunction of heart, lung, liver, kidney and other vital organs. Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L. ALT and AST < 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN. serum creatinine <1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify